NASDAQ:HURA TuHURA Biosciences Q4 2025 Earnings Report $1.91 -0.07 (-3.54%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$1.95 +0.04 (+2.09%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast TuHURA Biosciences EPS ResultsActual EPS-$0.13Consensus EPS -$0.12Beat/MissMissed by -$0.01One Year Ago EPSN/ATuHURA Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATuHURA Biosciences Announcement DetailsQuarterQ4 2025Date3/31/2026TimeBefore Market OpensConference Call DateTuesday, March 31, 2026Conference Call Time7:00AM ETUpcoming EarningsTuHURA Biosciences' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) TuHURA Biosciences Earnings HeadlinesTuHURA Biosciences Draws Additional Funds From Credit FacilitySeptember 24, 2026 | tipranks.comTuHURA Biosciences Expands Use of Revolving Credit FacilitySeptember 17, 2026 | tipranks.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely. | Altimetry (Ad)TuHURA Biosciences, Inc.: TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in ...September 16, 2026 | finanznachrichten.deTuHURA Biosciences Receives FDA IND Clearance For TBS-2025 In AMLSeptember 14, 2026 | rttnews.comTuHURA Biosciences Says FDA Clears Phase 1b Trial of TBS-2025 in Acute Myeloid LeukemiaSeptember 14, 2026 | finance.yahoo.comSee More TuHURA Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TuHURA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TuHURA Biosciences and other key companies, straight to your email. Email Address About TuHURA BiosciencesTuHURA Biosciences (NASDAQ:HURA) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is aimed at addressing primary and acquired resistance to existing cancer immunotherapies, including immune checkpoint inhibitors. TuHURA’s lead investigational product, IFx-2.0, is an intratumoral cancer immunotherapy designed to stimulate a patient’s immune system to recognize and attack tumor cells. The company is evaluating the candidate in clinical studies involving advanced solid tumors, including melanoma, with the goal of improving responses in patients whose cancers have not responded adequately to available treatments. TuHURA is headquartered in Tampa, Florida, and conducts its drug-development activities through clinical research and collaborations primarily in the United States. The company became publicly traded on Nasdaq under the symbol HURA following a business combination with Kintara Therapeutics. James Bianco, M.D., serves as president and chief executive officer.View TuHURA Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
